Novo shares moved lower on Monday. - Nichlas Pollier/Bloomberg News Novo Nordisk Chief Executive Mike Doustdar, who took over in 2025 promising to find a sustainable growth path, said the company will launch several new blockbusters over the next few years but investors aren't yet convinced the Danish drugmaker is close to finding its next Ozempic. Novo's shares were down roughly 6% on Monday during the company's investor day in London. Most Read from The Wall Street Journal The New Ways to Thrive at Work Now, According to Adam Grant Paramount Discussed $1.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.